The Oxford Drug Trial’s Fake Ivermectin Supply Chain Issue
The ongoing assault on ivermectin as a treatment for COVID continues, this time involving a wide-ranging drug trial establishing its effectiveness against the virus in the United Kingdom.
The government-backed Platform Randomised Trial of Treatments in the Community for Epidemic & Pandemic Illnesses (PRINCIPLE) playing out in Britain, is investigating Ivermectin as a possible home treatment for COVID.
But on December 14, 2021, the trial was put on hold due to “temporary supply issues” as reported by Medpage Today. It should be noted that when a drug trial is launched the trial supply of the drug being examined and investigated is secured.
Details on the depth or the cause of any supply issues were not provided. The trial’s joint chief investigator and press team declined to comment or respond to queries about the issue.
One of two organizations responsible for quality person release, importing, and labeling of ivermectin in the trial, Torbay & South Devon NHS Foundation Trust in England, also refused to provide information on the alleged supply chain issue or the status of the trial.
Edinbridge Pharmaceuticals, the manufacturer supplying the ivermectin, issued a statement saying the company “is not experiencing any supply issues related to its ivermectin tablets (3mg) product.”
The pharmaceutical company’s ivermectin tablets were added to the World Health Organization’s (WHO) Prequalified Medicines List in September of 2020, which certifies that a medicine meets “acceptable standards of quality, safety, and efficacy” for international procurement agencies to purchase and distribute in “resource-limited countries.”
While the halt on the trial was lifted as of Friday, PRINCIPLE has now paused the trial “for registrations over the Festive Break” and will “reopen for registrations on January 4th,” this according to the trial’s website.
At the trials launch, PRINCIPLE said the drug was safe and readily available, inferring there was an appropriate supply of the drug on hand.
Several notable doctors have taken issue with the trial’s sudden pause being predicated on the ivermectin supply.
Dr. Tess Lawrie, director of the Evidence-based Medicine Consultancy – whose company is associated with the WHO, said the supply issue citation was “plainly ridiculous…We are talking about a most abundant off-patent medicine that is produced in many countries around the world. There are many European manufacturers too, including Huvepharma in Bulgaria.”
Chief of the Division of Pulmonary & Critical Care Medicine at the Eastern Virginia Medical School, Dr. Paul Marik, said the reason given by PRINCIPLE was “nonsense…It’s clear this is an ominous plot. A supply issue with ivermectin; you must be kidding. After 3.7 billion doses having been dispensed in the last 2 decades; we have a supply issue; what nonsense.”
Why This Is Important
From the very onset of the COVID pandemic, the international medical community has debated the use of ivermectin as both a preventative and a treatment for the virus. In fact, the number of physicians and scientists that advocate for the use of ivermectin only grows to this day.
In fact, to date, 31 countries around the world have authorized the use of ivermectin for the treatment and prevention of COVID, including India, Japan, and an assortment of African nations that had very few fatalities after ivermectin’s employment.
So, with a medication certified safe by the WHO and clinically proven to be effective against the COVID virus in dozens of countries around the world, how can it be that there aren’t nefarious forces of profiteering at play?
The inventor of the mRNA vaccine technology, Dr. Robert Malone, says the likelihood there is a shortage of ivermectin “doesn’t pass the smell test. He went on record alleging the Oxford University team was either lying or incompetent.
“The first thing you do before you launch the study is you lock down your trial supply so that one completely fails the sniff test,” Malone said. “Either they’re grossly incompetent at the University of Oxford or lying. It’s one or the other because [the] worldwide supply of ivermectin is enormous, and there’s no way that a competent clinical research team would not have locked down their trial supply.”
If the government of the United States – to include the medical bureaucracy (read: the CDC, HIH, Big Pharma and the medical insurance companies) is so dedicated to following the science instead of ginning up profits, why is there so much unwarranted push back on ivermectin?
Anyone who isn’t overly alarmed at the nefariousness surrounding the entirety of the COVID issue – from the human manipulation of the coronavirus to the Wuhan lab leak to the censorship of medical debate about treatment to the grotesque profits being gleaned by Big Pharma, their investors and the medical bureaucracy, is living in a bubble.
In the end, people need to go to prison over the gross malpractice being perpetrated upon the people of the world. To wit, this event should expose just how corrupt the global elite really are, and just how much they couldn’t care less about the average person.